Healthcare policy in the United States is not made in a vacuum. It is made in a political environment populated by organized actors with substantial resources, sustained presence, and clear financial interests in the policy outcomes they seek to influence. Understanding who those actors are, what organizational capacity they bring to the policy environment, and what the asymmetry between organized industry interests and the diffuse public interest actually looks like in practice is necessary for understanding why the healthcare system looks the way it does — and why changing it has proven so resistant to the periodic political energy that reform efforts generate.
This is not a corruption story, though corruption exists at the margins of any system involving large amounts of money and political influence. It is a structural story. The organized interests that shape healthcare policy — pharmaceutical manufacturers, hospital systems, insurance companies, physician organizations, medical device makers — are doing what organized interests do in a democratic system: advocating for policies that serve their members, deploying resources to influence the political process, and maintaining the sustained organizational presence that episodic civic mobilization cannot match. The problem is not their behavior. The problem is the absence of a countervailing organizational force with comparable staying power — the civic infrastructure gap that Why Healthcare Reform Keeps Failing identifies as the structural condition underlying decades of incomplete reform.
This article maps the major actors in the healthcare policy environment: who they are, what resources they deploy, how they exercise influence, and where the asymmetry between organized industry and organized civic interest is most consequential. The consolidation that has amplified the market and political power of major healthcare institutions is examined in How Consolidation Drives Healthcare Costs. This article focuses on how that power translates into political influence over the policies that govern the system.
The Pharmaceutical Industry
The pharmaceutical industry — manufacturers of branded drugs, generics, and biologics — is among the most politically active and most consistently effective industries in the American healthcare policy environment. It spends more on federal lobbying than any other industry, has done so for most of the past two decades, and has successfully defended its core pricing and patent interests against reform efforts that commanded broad public support.
PhRMA — the Pharmaceutical Research and Manufacturers of America — is the primary trade association for branded drug manufacturers and one of the most well-resourced lobbying organizations in Washington. Its member companies include the largest pharmaceutical manufacturers globally, and PhRMA’s political spending — on lobbying, on campaign contributions through PACs, and on issue advertising — is substantial across both federal and state policy environments. Individual member companies maintain their own lobbying operations in addition to PhRMA’s industry-level advocacy, creating a layered presence that can be deployed at multiple levels of the policy process simultaneously.
The pharmaceutical industry’s political effectiveness is not simply a function of money. It rests on several structural advantages. The industry employs former members of Congress, former congressional staff, former executive branch officials, and former regulators in its lobbying operations — people with direct relationships to current decision-makers and detailed knowledge of legislative and regulatory processes. It conducts significant research and manufacturing in congressional districts across the country, giving members of Congress local employment and economic interests that align with the industry’s policy preferences. It funds patient advocacy organizations — a practice that creates the appearance of patient support for industry-favorable policies and that has been documented in research on pharmaceutical industry relationships with advocacy groups. And it frames its policy arguments in terms of innovation — the claim that high drug prices fund the research that produces future cures — that resonates in a political environment that values medical progress.
The clearest demonstration of the pharmaceutical industry’s political effectiveness is the 2003 provision in the Medicare Part D statute that prohibited Medicare from negotiating drug prices — a provision that was unique among public insurance programs in the United States and among wealthy countries globally, and that was explicitly written to protect manufacturer pricing power. This provision survived for nearly two decades before the Inflation Reduction Act of 2022 created limited negotiation authority for a small number of drugs. The political effort to maintain the prohibition on negotiation, against repeated reform attempts and consistent public support for Medicare drug price negotiation, is a case study in how organized industry interest sustains policy outcomes that serve its financial interests against the preferences of a diffuse public majority.
Hospital Systems and Health Systems
The hospital industry — represented nationally by the American Hospital Association and by numerous regional and specialty hospital associations — is another dominant actor in the healthcare policy environment. Hospitals are present in virtually every congressional district, employ large workforces, and are anchors of local economies in ways that give their political interests a geographic breadth that few other industries can match.
The political economy of hospital advocacy is distinctive because hospitals operate across the ideological spectrum of American communities. Rural hospitals in conservative districts and urban safety-net hospitals in progressive districts both have strong institutional interests in healthcare policy — in Medicaid payment rates, in graduate medical education funding, in regulatory requirements, in certificate of need laws that limit competitor entry — and both can mobilize local political support from elected officials who would not otherwise agree on healthcare questions. This cross-partisan geographic presence gives the hospital industry unusual political reach relative to its direct campaign spending.
Hospital systems have also benefited from the consolidation trend examined in How Consolidation Drives Healthcare Costs. As hospital systems have grown larger and gained market dominance in their regions, they have also grown more politically powerful — with larger lobbying budgets, more employees whose livelihoods are tied to the system’s political success, and more economic heft in the communities where elected officials must win elections. The relationship between market consolidation and political power is not incidental: a health system that controls most of the hospital capacity in a region is also a political actor that local elected officials are reluctant to antagonize.
The American Hospital Association’s lobbying positions are complex and do not map neatly onto a simple pro-or-anti-reform position. Hospitals have supported some coverage expansions — Medicaid expansion increases the number of insured patients and reduces uncompensated care — while opposing payment rate reductions, administrative requirements that increase compliance costs, and antitrust enforcement that would limit consolidation. The hospital industry’s political influence is deployed strategically across these positions, supporting coverage policies that benefit its revenue while opposing cost control policies that would reduce its payment rates or constrain its market power.
The Insurance Industry
The health insurance industry — represented primarily by AHIP, America’s Health Insurance Plans — is a major political actor with interests that are more complex than simple opposition to healthcare reform. Insurers have supported some elements of the ACA — particularly the individual mandate and the expansion of the insured pool that increased their market — while opposing others, including the public option that would compete with their products and the medical loss ratio requirements that constrain their administrative spending and profit margins.
The insurance industry’s political influence operates at both federal and state levels. State insurance regulation — which governs premium rates, network adequacy requirements, benefit mandates, and market conduct — is a major site of insurance industry lobbying. The variation across states in how aggressively insurance markets are regulated reflects partly the variation in insurance industry political influence at the state level.
The large insurers’ consolidation into a small number of dominant national companies, described in How Consolidation Drives Healthcare Costs, has amplified their political resources relative to the fragmented insurance market of an earlier era. UnitedHealth Group, Anthem/Elevance, Aetna/CVS, Cigna, and Humana together have lobbying operations and political spending capacities that dwarf what smaller insurers could deploy, and their scale gives them relationships with elected officials across the country through their enrollment presence in virtually every congressional district.
The insurance industry’s opposition to a public option — which is the reform proposal most directly competitive with its core business — has been sustained and well-resourced across multiple reform cycles. The arguments deployed against a public option include concerns about government competition with private enterprise, the cross-subsidy argument that a public plan paying lower rates would shift costs to private payers, and the administrative disruption of transitioning employer coverage. These arguments are not without substance — the policy design of a public option matters enormously for its effects — but they are also aligned with the industry’s financial interest in the absence of government competition, which gives them a motivated quality that should be weighed in evaluating them.
Physician Organizations
The American Medical Association is the largest and historically most influential physician organization in American healthcare policy. Its political influence has waxed and waned over the decades — it was the primary organized opposition to Medicare in 1965, running the Harry and Louise predecessor campaign against “socialized medicine,” and its membership as a share of the physician workforce has declined from its mid-twentieth century peak. But the AMA remains a significant political actor with substantial lobbying resources and a political action committee that is among the largest in the healthcare sector.
The AMA’s policy positions are not uniformly opposed to healthcare reform. On administrative burden — prior authorization, electronic health record requirements, billing complexity — the AMA has advocated for simplification that would benefit physicians. On scope of practice — the authority of nurse practitioners, physician assistants, and other advanced practice providers to practice without physician supervision — the AMA has consistently opposed expansion, a position that reflects physician economic interest in maintaining professional exclusivity as well as some genuine clinical quality arguments. On coverage expansion, AMA positions have been more mixed, supporting coverage expansions that increase the number of insured patients while opposing payment rate reductions.
Specialty societies — the American College of Cardiology, the American College of Surgeons, the American Academy of Dermatology, and dozens of others — are separate political actors from the AMA and often have more specific and more effectively deployed political influence in their domains. Specialty societies have been particularly effective at influencing the relative value unit calculations that determine Medicare payment rates for their specialties’ services — the technical process by which Medicare physician payment is set involves specialty society input that has historically favored procedural specialties relative to primary care cognitive work.
The political division within the physician community — between primary care physicians whose economic interests align more closely with reform proposals that improve primary care payment and access, and procedural specialists whose economic interests are more tied to current payment structures — means that physician political influence is not monolithic. Primary care physician organizations have at times been aligned with reform advocates against the AMA and specialty society positions.
The Pharmacy Benefit Manager Sector
Pharmacy Benefit Managers — the intermediaries who manage prescription drug benefits for insurers and employers — have grown from a relatively obscure back-office function into a major economic and political actor in American healthcare over the past two decades. The three largest PBMs — CVS Caremark, Express Scripts (now part of Cigna), and OptumRx (part of UnitedHealth Group) — together manage the prescription drug benefits of the majority of Americans with insurance coverage.
The PBM sector’s political influence is exercised primarily to resist transparency requirements and regulatory scrutiny of their business practices. The opacity of PBM operations — the rebate structures, the spread pricing practices, the formulary management decisions — has been a target of reform proposals from legislators on both sides of the aisle, and PBM lobbying has been directed at limiting the scope and impact of those requirements. The vertical integration of PBMs into major insurance companies has made the regulatory question more complex, as proposals to regulate PBMs affect the same entities that manage insurance coverage.
Congressional scrutiny of PBM practices has increased substantially over the past several years, with bipartisan interest in transparency and reform. Legislative proposals to require PBMs to pass rebates through to patients at the point of sale, to restrict spread pricing in Medicaid managed care, and to require disclosure of PBM contracts have advanced in various forms. The PBM industry has deployed significant lobbying resources against these proposals while supporting some transparency requirements that are less threatening to its business model.
Patient Advocacy Organizations and Their Complications
Patient advocacy organizations — disease-specific nonprofits that represent the interests of people with particular conditions — are nominally on the opposite side of the power asymmetry from industry, representing patient interests rather than industry interests. In practice, the picture is considerably more complex.
Many patient advocacy organizations receive substantial funding from the pharmaceutical and device industries. Research by academic health policy scholars has documented that a significant share of major patient advocacy organizations receive pharmaceutical industry funding, and that organizations with pharmaceutical funding are more likely to take policy positions favorable to pharmaceutical industry interests — on drug pricing, on Medicare negotiation authority, on FDA approval processes — than organizations without pharmaceutical funding. This relationship does not mean that patient advocacy organizations are simply industry fronts; many do important work advocating for research funding, coverage policies, and access to care that genuinely serves patient interests. It does mean that the appearance of patient support for industry-favorable policies requires scrutiny about funding sources and potential conflicts of interest.
The patient advocacy organizations with the most sustained and effective political presence are generally those with the most members, the most engagement from members who can communicate directly with elected officials, and the most institutional independence from industry funding. AARP — the membership organization for Americans 50 and older — is among the most politically effective patient-adjacent organizations in healthcare, with a membership base of tens of millions and a sustained presence in healthcare policy discussions that reflects genuine member interests in Medicare, prescription drug pricing, and long-term care. Disease-specific organizations with large and active memberships — several cancer advocacy organizations, diabetes advocacy organizations — have also achieved meaningful political effectiveness on specific policy questions.
The Civic Counterweight: What Exists and What Doesn’t
Against the organized industry interests described above, what civic capacity exists to represent the interests of patients, workers, and communities in healthcare policy?
Healthcare worker unions — particularly the unions representing nurses, hospital workers, and home health aides — are among the most organizationally capable civic actors in healthcare policy. Unions bring the sustained organizational infrastructure, the member engagement, and the geographic presence that effective political advocacy requires. National Nurses United has been among the most consistent advocates for Medicare for All; SEIU’s healthcare locals have been active in Medicaid expansion campaigns and in minimum wage campaigns that affect the direct care workforce. Where unions are strong, they represent a genuine organizational counterweight to industry advocacy.
But the unionization rate among healthcare workers is uneven — higher among nurses and hospital workers in certain regions, much lower among physicians and home health aides — and union political influence in healthcare policy has not been sufficient to produce the structural reforms that worker and patient interests would support. The broader decline in union density across the American economy has reduced the organizational capacity that unions represent as a civic counterweight.
Community health organizations, consumer advocacy groups, and disease-specific patient organizations contribute to the civic side of healthcare policy advocacy, but they typically operate without the sustained resources, the institutional permanence, or the geographic breadth of industry organizations. They mobilize effectively around specific legislative moments — during ACA passage, during repeal attempts — but the between-moment organizational capacity that tracks implementation, monitors accountability, and maintains pressure across administrations is less developed.
The result is the asymmetry that Why Healthcare Reform Keeps Failing identifies as the structural condition underlying reform failure: organized industry interests with sustained presence, substantial resources, and institutional memory operate continuously in the policy environment, while the civic capacity to counterbalance them mobilizes episodically and does not maintain the organizational continuity that cross-cycle accountability requires.
Building that civic capacity — not as a mirror of industry advocacy, but as the organizational infrastructure through which patients, caregivers, healthcare workers, and affected communities can participate continuously in shaping the policies that govern their care — is part of what platforms like America’s Plan are designed to address. The power map documented here is not a fixed feature of American healthcare governance. It is the product of organizational choices that have accumulated over decades and that can, with sustained effort and the right organizational infrastructure, be made differently.
This article was researched and drafted with AI assistance under human review. See our full AI and editorial practices.